Ocular Hypertension Pipeline Review, H1 2019 by Stage of Development, Drug Target, MoA, RoA and Molecule Type - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Ocular Hypertension - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Ocular Hypertension - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 13, 10, 3 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Key Topics Covered:

1. Introduction
2. Ocular Hypertension - Overview
3. Ocular Hypertension - Therapeutics Development
4. Ocular Hypertension - Therapeutics Assessment
5. Ocular Hypertension - Companies Involved in Therapeutics Development
6. Ocular Hypertension - Drug Profiles
7. Ocular Hypertension - Dormant Projects
8. Ocular Hypertension - Discontinued Products
9. Ocular Hypertension - Product Development Milestones
10. Appendix

Companies Mentioned

• Aerie Pharmaceuticals Inc
• Allergan Plc
• Angelini Group
• Chong Kun Dang Pharmaceutical Corp
• D. Western Therapeutics Institute Inc
• Kowa Co Ltd
• Laboratorios SALVAT SA
• Laboratorios Sophia SA de CV
• Lee's Pharmaceutical Holdings Ltd
• Neurim Pharmaceuticals Ltd
• NicOx SA
• Novartis AG
• Ocular Therapeutix Inc
• Santen Pharmaceutical Co Ltd
• Senju Pharmaceutical Co Ltd
• Sun Pharma Advanced Research Company Ltd
• Sylentis SAU
• Taejoon Pharm Co Ltd
• Takeda Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/n354as